Rizatriptan oral film - IntelGenx
Alternative Names: INT 0008/2007; INT 0008/2008; INT0008; RHB-103; RIZAFILM; RIZAFILM VersaFilm; RIZAPORT; RIZAPORT® VersaFilm®; Rizatriptan benzoate - IntelGenxLatest Information Update: 26 Mar 2024
At a glance
- Originator IntelGenx Corp.
- Developer Exeltis; IntelGenx Corp.; RedHill Biopharma
- Class Antimigraines; Small molecules; Triazoles; Tryptamines
- Mechanism of Action Serotonin 1B receptor agonists; Serotonin 1D receptor agonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
- Available For Licensing Yes - Migraine
Highest Development Phases
- Marketed Migraine
Most Recent Events
- 26 Sep 2023 Gensco® Pharma in partnership with IntelGenx plans the launch of Rizatriptan oral film in USA in the second quarter of 2024
- 17 Apr 2023 IntelGenx in collaboration with its commercialization partner Gensco Laboratories intends to launch rizatriptan oral film for Migraine in USA (PO)
- 14 Apr 2023 Registered for Migraine (In adults, In adolescents) in USA (PO)